Key result
Therapeutic agents targeting the prostacyclin, endothelin, and nitric oxide pathways improve the prognosis of patients with pulmonary arterial hypertension.
Why the study?
To provide an overview of current therapeutic agents and introduce new drug therapies targeting prostacyclin, endothelin, and nitric oxide pathways in pulmonary arterial hypertension.
This review provides an overview of current and emerging drug therapies for pulmonary arterial hypertension targeting the prostacyclin, endothelin, and nitric oxide pathways.
Pulmonary arterial hypertension (PAH) is a disease in which stenosis or obstruction of the pulmonary arteries (PAs) causes an increase in PA pressure, leading to right-sided heart failure and death. Basic research has revealed a decrease in the levels of endogenous vasodilators, such as prostacyclin, and an increase in the levels of endogenous vasoconstrictors, such as endothelin, in patients with PAH, leading to the development of therapeutic agents. Currently, therapeutic agents for PAH target three pathways that are selective for PAs: the prostacyclin, endothelin, and nitric oxide pathways. These treatments improve the prognosis of PAH patients. In this review, we introduce new drug therapies and provide an overview of the current therapeutic agents.
No takes yet. Share an insight, caveat, or question.
Otani et al. (2022) conducted a review in Pulmonary arterial hypertension. Therapeutic agents targeting prostacyclin, endothelin, and nitric oxide pathways was evaluated. Therapeutic agents targeting the prostacyclin, endothelin, and nitric oxide pathways improve the prognosis of patients with pulmonary arterial hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: